MannKind Corporation (Nasdaq:MNKD), announced that it presented new scientific data in an oral and poster presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany....
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst $NKTR via | @FierceBiotech https://t.co/3L9zTcJpuz pic.twitter.com/2rC8BJ4f18— medtech[y] (@medtechy) October 1, 2018
Drugmakers are using an unusual tactic to compete in a new class of medication to treat the 38 million Americans who have migraines $AMGN $NVS | https://t.co/B7ob6TjScZ pic.twitter.com/egNVETZ05i— medtech[y] (@medtechy) September 28, 2018
GW Pharma, armed with best-case DEA decision, charts path to Epidiolex launch https://t.co/H3UKs1xyRW— FiercePharma (@FiercePharma) September 27, 2018
Novartis will probably have to go further to meet earnings targets as more patents expire, say analysts https://t.co/3swfxQiATr— The Wall Street Journal (@WSJ) September 25, 2018
Good morning. If you’re just waking up, $AMRN is trading at $10. That a 200%-plus move. Grab some coffee and read: https://t.co/P53RVTKNM8— Adam Feuerstein (@adamfeuerstein) September 24, 2018
AbbVie accused of paying kickbacks, using a stealthy network to promote Humira $ABBV | https://t.co/aH8W0nKjTX pic.twitter.com/3A5Mpf8A61— medtech[y] (@medtechy) September 19, 2018
In a bid to appeal to millennials, Botox-maker Allergan is asking them if they're 'bo-curious' $AGN | https://t.co/wRRVttWrwQ pic.twitter.com/IZQJO0Yee8— medtech[y] (@medtechy) September 17, 2018
According to WSJ reporter, John Carreyrou, the blood-testing company,Theranos, has emailed shareholders and has decided to shut the company down. ...
MannKind's stock ($MNKD) is up 51% in midday trading as they have entered into a worldwide exclusive licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil...